Genomic Health has released positive results from nine studies utilizing the Oncotype DX, a breast cancer test, in patients with early-stage breast cancer.
The Oncotype DX breast cancer test analyses the expression of 21 genes of an individual breast cancer tumour to generate a Recurrence Score (RS) that predicts the chemotherapy benefit and the likelihood of cancer recurrence for early-stage patients.
The studies involved a total of 1,154 early-stage breast cancer patients across UK, Germany, Spain, Greece, Japan, Singapore, and Hungary.
The studies revealed that the RS score provided by the Oncotype DX test changed physicians’ treatment recommendations in approximately 35% of cases.
The study also lead to an overall reduction of chemotherapy recommendations or use by approximately 24%.
In the UK, Germany and Spain, the RS score changed physicians’ treatment recommendations in approximately 33% of cases, which is similar to what was seen in the US.